


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:  
File Information Unit  
Crystal Plaza Three, Room 1001  
2021 South Clark Place  
Arlington, VA  
Telephone: (703) 308-2733



In re Application of

Wang

Application Number

08/887,977

Filed

7-3-97

Paper No.

#17

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. \_\_\_\_\_, page, \_\_\_\_\_ line \_\_\_\_\_.

United States Patent Number 6,723,520, column FF, line, \_\_\_\_\_ or

WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

### Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:  
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
  - the file contents;
  - the pending application as originally filed; or
  - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
  - the pending application as originally filed.

John Semiklov  
Signature

John Semiklov  
Typed or printed name

Registration Number, if applicable

703-479-5350

Telephone Number

04-13-05

Date

FOR PTO USE ONLY

Approved by: \_\_\_\_\_

(Initials)

Unit:

File Information Unit

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1001, 2021 South Clark Place, Arlington, VA.



(12) **United States Patent**  
**Wang et al.**

(10) **Patent No.: US 6,723,520 B2**  
(45) **Date of Patent: Apr. 20, 2004**

(54) **ANTIBODIES THAT BIND CHEMOKINE  
TECK**

(75) **Inventors:** **Wei Wang**, Palo Alto, CA (US); **Kurt C. Gish**, Sunnyvale, CA (US); **Thomas J. Schall**, Menlo Park, CA (US); **Alain Vicari**, Mountain View, CA (US); **Albert Zlotnik**, Palo Alto, CA (US)

(73) **Assignee:** **Schering Corporation**, Kenilworth, NJ (US)

(\*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 4 days.

(21) **Appl. No.:** **10/039,659**

(22) **Filed:** **Jan. 3, 2002**

(65) **Prior Publication Data**

US 2003/0018167 A1 Jan. 23, 2003

#### **Related U.S. Application Data**

(62) Division of application No. 08/887,977, filed on Jul. 3, 1997, now abandoned.

(60) Provisional application No. 60/021,664, filed on Jul. 5, 1996, provisional application No. 60/028,329, filed on Oct. 11, 1996, and provisional application No. 60/048,593, filed on Jun. 4, 1997.

(51) **Int. Cl.<sup>7</sup>** ..... **C07K 16/00; C07K 16/24; C07K 16/46; C07K 33/68**

(52) **U.S. Cl.** ..... **435/7.1; 435/7.6; 435/7.9; 530/387.1; 530/387.3; 530/387.9; 530/388.1; 530/388.23; 530/389.1; 530/391.1; 530/391.3**

(58) **Field of Search** ..... **530/387.1, 387.3, 530/387.9, 388.1, 388.23, 389.1, 389.2, 391.1, 391.3; 435/7.1, 7.6, 7.72, 7.9**

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

5,681,930 A \* 10/1997 Radka et al.  
5,981,231 A \* 11/1999 Wei et al.

#### **FOREIGN PATENT DOCUMENTS**

WO	WO 96/05856	2/1996
WO	WO 96/16979	6/1996
WO	WO 96/22374	7/1996
WO	WO 96/24668	8/1996

#### **OTHER PUBLICATIONS**

Wells, 1990, *Biochemistry* 29:8509-8519.\*  
Ngo et al., 1994, *The Protein Folding Problem and Tertiary Structure Prediction*, Merz et al., eds., Birkhauser, Boston, pp. 491-435.\*  
Bork, 2000, *Genome Research* 10:398-400.\*  
Skolnick et al., 2000, *Trends in Biotech.* 18:34-39.\*  
Doerks et al., 1998, *Trends in Genetics* 14:248-250.\*  
Smith et al., 1997, *Nature Biotechnology* 15:1222-1223.\*  
Brenner, 1999, *Trends in Genetics* 15:132-133.\*  
Bork et al., 1996, *Trends in Genetics* 12:425-427.\*

Sunil K. Ahuja, et al., *Immunol. Today* 15:281-287, 1994, "Chemokine Receptors and Molecular Mimicry".

Ghalig Alkatib, et al., *Science* 272:1955-1958, Jun. 28, 1996. "CC CKR5: A Rantes, MIP-1 $\alpha$ , MIP-1 $\beta$  Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1".

Masataka Baba, et al., *J. Biological Chemistry*, 272(23):14893-14898, Jun. 6, 1997. "Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC".

Kevin B. Bacon, et al., *Int. Arch. Allergy Immunol.* 109:97-109, 1996. "Chemokines as Mediators of Allergic Inflammation".

Michael Balter, *Science* 272:1740, Jun. 21, 1996. "A Second Coreceptor for HIV in Early Stages of Infection".

T.I. Bonner, et al., *EMBL Database*, Entry HS459841, Accession No. U45984, Apr. 5, 1996. "Cloning, tissue distribution and chromosomal localization of a potential G protein-linked receptor".

Ian Clark-Lewis, et al., *J. Leukoc. Biol.* 57:703-711, 1995. "Structure-Activity Relationships of Chemokines".

Hongkui Deng, et al., *Nature* 381:661-666, Jun. 20, 1996. "Identification of a Major Co-Receptor for Primary Isolates of HIV-1".

Tatjana Dragic, et al., *Nature* 381:667-673, Jun. 20, 1996. "HIV Entry into CD4+ Cells is Mediated by the Chemokine Receptor CC-CKR-5".

Angela M. Gronenborn, et al., *Prot. Engg.* 4:263-269, 1991. "Modeling the Three-Dimensional Structure of the Monocyte Chemo-Attractant and Activating Protein MCAF/MCP-1 on the Basis of the Solution Structure of Interleukin-8".

Kunio Hieshima, et al., *J. Biological Chemistry*, 272(9):5846-5853, Feb. 28, 1997. "Molecular Cloning of a Novel Human CC Chemokine Liver and Activation-regulated Chemokine (LARC) Expressed in Liver".

L. Hillier, et al., *EMBL Database*, Entry HS519338, Accession No. W05519, May 8, 1996. "za81g11.1 Soares fetal lung NbHL19W Homo sapiens".

L. Hillier, et al., *EMBL Database*, Entry HS958307, Accession No. N73958, Mar. 23, 1996. "The WashU-Merck EST project: za74f04.s1 Homo sapiens cDNA clone 298303.3".  
R. Horuk, et al., *J. Leukoc. Biol.* 59:29-38, Jan. 1996. "The Duffy Antigen Receptor for Chemokines: Structural Analysis and Expression in the Brain".

Richard Horuk, *TIPS* 15:159-165, May 1994. "Molecular Properties of the Chemokine Receptor Family".

(List continued on next page.)

*Primary Examiner*—Elizabeth Kemmerer

(74) *Attorney, Agent, or Firm*—Edwin P. Ching; Sheela Mohan-Peterson; Sandy Zaradic

(57) **ABSTRACT**

Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods of using said reagents and diagnostic kits are also provided.

**22 Claims, 1 Drawing Sheet**